ABOUT PRECISION ADVANCE
Since 2013, Precision’s interdisciplinary teams have been advancing clinical, manufacturing and commercialization solutions to help innovators transform patient lives. We know that delivering a cell or gene therapy to market requires a nuanced, comprehensive and integrated approach, scientific and manufacturing expertise, and the right partner. That’s precisely why we’ve launched Precision ADVANCE, a collection of interconnected services and complementary teams uniquely focus on the complexities of clinical, regulatory, manufacturing, and commercial needs to successfully bring cell or gene therapies to market.
In this Precision ADVANCE panel, industry experts share perspectives on the current state of the cell and gene therapy industry and provide key insights in shortening time-to-market for advanced therapies.
In this webinar, Carolyn Morgan of PRECISIONeffect moderates an expert panel exploring the challenges of commercializing a cell or gene therapy from industry trailblazers that share lessons learned from prior launches and discuss how cell and gene therapies are reshaping commercializing strategies. Some of the topics explored will be tensions between cost-effectiveness and affordability, evidence generation strategies and development, and communication to payers and health technology appraisal organizations.
Rare disease trials are complex under the best of circumstances—and the coronavirus pandemic has only complicated things. In this podcast, Precision’s Thijs Opdeweegh, Director, Clinical Business Solutions, and Kristi Clark, Senior Vice President, Project Management and Clinical Operations, explore the impact of decentralized operations on rare disease patients, and which new approaches are likely to become the “new normal” after COVID.